002422 科伦药业
交易中 03-12 13:41:09
资讯
新帖
简况
英硅智能与Liquid AI达成合作；氢溴酸他泽司他片被召回
21世纪经济报道 · 03-10 08:03
英硅智能与Liquid AI达成合作；氢溴酸他泽司他片被召回
科伦药业(002422.SZ)：SKB575新药临床试验申请获批准
智通财经 · 03-09 17:04
科伦药业(002422.SZ)：SKB575新药临床试验申请获批准
3月6日科伦药业涨7.93%，中欧医疗健康混合A基金重仓该股
证券之星 · 03-06
3月6日科伦药业涨7.93%，中欧医疗健康混合A基金重仓该股
股市必读：科伦药业（002422）3月4日董秘有最新回复
证券之星 · 03-05
股市必读：科伦药业（002422）3月4日董秘有最新回复
科伦药业（002422）发布关于首次回购公司股份的公告，3月2日股价下跌1.11%
证券之星 · 03-02
科伦药业（002422）发布关于首次回购公司股份的公告，3月2日股价下跌1.11%
股市必读：科伦药业（002422）2月25日董秘有最新回复
证券之星 · 02-26
股市必读：科伦药业（002422）2月25日董秘有最新回复
科伦药业（002422）披露回购公司股份进展公告，2月3日股价上涨0.86%
证券之星 · 02-03
科伦药业（002422）披露回购公司股份进展公告，2月3日股价上涨0.86%
科伦药业：公司不涉及该病毒的药物
证券之星 · 01-28
科伦药业：公司不涉及该病毒的药物
科伦药业（002422）披露2026年度第一期科技创新债券发行结果，1月21日股价下跌1.23%
证券之星 · 01-21
科伦药业（002422）披露2026年度第一期科技创新债券发行结果，1月21日股价下跌1.23%
科伦药业涨6.19%，中国银河二个月前给出“买入”评级
证券之星 · 01-08
科伦药业涨6.19%，中国银河二个月前给出“买入”评级
科伦药业董事会通过股份回购方案，披露决议前十大股东持股情况
中金财经 · 01-06
科伦药业董事会通过股份回购方案，披露决议前十大股东持股情况
科伦药业(002422.SZ)拟斥5000万元至1亿元实施回购
智通财经 · 01-05
科伦药业(002422.SZ)拟斥5000万元至1亿元实施回购
科伦药业（002422）披露控股子公司拟实施2025年股份激励计划，12月11日股价下跌1.6%
证券之星 · 2025-12-11
科伦药业（002422）披露控股子公司拟实施2025年股份激励计划，12月11日股价下跌1.6%
科伦药业(002422.SZ)：公司5个品种药品纳入国家医保目录
智通财经 · 2025-12-08
科伦药业(002422.SZ)：公司5个品种药品纳入国家医保目录
科伦药业最新公告：科伦博泰与CrescentBiopharma建立战略合作伙伴关系涉及科伦博泰的SKB105和Crescent的CR-001两款候选药物
证券之星 · 2025-12-04
科伦药业最新公告：科伦博泰与CrescentBiopharma建立战略合作伙伴关系涉及科伦博泰的SKB105和Crescent的CR-001两款候选药物
Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项
美股速递 · 2025-12-04
Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项
Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款
美股速递 · 2025-12-04
Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款
科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法
美股速递 · 2025-12-04
科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法
科伦药业新注册《科伦悦签小程序系统1.0》等2个项目的软件著作权
证券之星 · 2025-11-15
科伦药业新注册《科伦悦签小程序系统1.0》等2个项目的软件著作权
科伦药业最新公告：棕榈酸帕利哌酮注射液获得药品注册批准为全球首个获批的每月给药一次的长效非典型抗精神病药
证券之星 · 2025-11-14
科伦药业最新公告：棕榈酸帕利哌酮注射液获得药品注册批准为全球首个获批的每月给药一次的长效非典型抗精神病药
公司概况
公司名称：
四川科伦药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-06-03
主营业务：
四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。
发行价格：
83.36
{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"科伦药业","latestPrice":32.75,"timestamp":1773294069000,"preClose":33.25,"halted":0,"volume":5893500,"delay":0,"changeRate":-0.015,"floatShares":1306000000,"shares":1598000000,"eps":1.0423,"marketStatus":"交易中","change":-0.5,"latestTime":"03-12 13:41:09","open":33.18,"high":33.24,"low":32.51,"amount":193000000,"amplitude":0.022,"askPrice":32.76,"askSize":79,"bidPrice":32.75,"bidSize":3,"shortable":0,"etf":0,"ttmEps":1.0423,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1773298800000},"marketStatusCode":2,"adr":0,"adjPreClose":33.25,"symbolType":"stock","openAndCloseTimeList":[[1773279000000,1773286200000],[1773291600000,1773298800000]],"highLimit":36.58,"lowLimit":29.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1598053372,"isCdr":false,"pbRate":2.24,"roa":"--","peRate":31.420896,"roe":"5.18%","epsLYR":1.86,"committee":-0.162939,"marketValue":52336000000,"turnoverRate":0.0045,"status":1,"floatMarketCap":42768000000},"requestUrl":"/m/hq/s/002422/wiki","defaultTab":"wiki","newsList":[{"id":"2618055516","title":"英硅智能与Liquid AI达成合作；氢溴酸他泽司他片被召回","url":"https://stock-news.laohu8.com/highlight/detail?id=2618055516","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618055516?lang=zh_cn&edition=full","pubTime":"2026-03-10 08:03","pubTimestamp":1773101006,"startTime":"0","endTime":"0","summary":"政策动向氢溴酸他泽司他片启动召回程序国家医保局3月9日消息显示，和黄医药（中国）有限公司发布公告，对其授权引进产品氢溴酸他泽司他片（商品名：达唯珂）启动撤市及产品召回程序。据此，自2026年3月9日起，撤销氢溴酸他泽司他片在全国各省级医药采购平台挂网，并根据企业申请，将氢溴酸他泽司他片移出《商业健康保险创新药品目录（2025年）》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103666774021.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103666774021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892789.USD","LU1255011170.USD","LU2097828557.USD","LU2328871848.SGD","GIPR","BK0196","LU2097828474.EUR","LU1997244956.HKD","BK0096","LU1328615791.USD","TSLP","LU1997245177.USD","LU1064130708.USD","LU0405327148.USD","BK0188","BK0060","BK0012","BK0187","LU2495084118.USD","LU1820825898.SGD","LU1781817850.SGD","LU2097828631.EUR","LU0405327494.USD","600196","LU1934453819.USD","LU1064131003.USD","BK0183","LU1979443071.USD","LU1146622755.USD","LU2289578879.USD","LU2148510915.USD","002422","BK0175","688621","BK0239","LU1655091616.SGD","BK4160","LU1969619763.USD","600276","LU2488822045.USD","LU2580892862.HKD","LU2097828714.EUR","LU1580142542.USD","IND","LU2097828805.USD","BK0216","LU1997245094.SGD","BK0028"],"gpt_icon":0},{"id":"2618664977","title":"科伦药业(002422.SZ)：SKB575新药临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618664977","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618664977?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:04","pubTimestamp":1773047075,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)公告，公司近日获悉，公司控股子公司四川科伦博泰生物医药股份有限公司(简称“科伦博泰”)与和铂医药控股有限公司(简称“和铂医药”)合作研发的靶向胸腺基质淋巴细胞生成素(TSLP)及一个未公开靶点的长效双特异性抗体(bsAb)SKB575(亦称HBM7575)的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准，用于治疗特应性皮炎。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦药业(002422.SZ)：SKB575新药临床试验申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","LU1979443071.USD","002422","BK0060","LU1934453819.USD","LU1064130708.USD","BK0239","LU2148510915.USD"],"gpt_icon":0},{"id":"2617683495","title":"3月6日科伦药业涨7.93%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617683495?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:27","pubTimestamp":1772785676,"startTime":"0","endTime":"0","summary":"证券之星消息，3月6日科伦药业涨7.93%，收盘报32.68元，换手率1.87%，成交量24.36万手，成交额7.78亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共74家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元，最新净值1.6726，较上一交易日上涨0.9%，近一年上涨6.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600025963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","159760","LU2148510915.USD","002422","LU1064131003.USD","LU1934453819.USD","LU1979443071.USD","BK0239","LU1064130708.USD"],"gpt_icon":0},{"id":"2617557198","title":"股市必读：科伦药业（002422）3月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2617557198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617557198?lang=zh_cn&edition=full","pubTime":"2026-03-05 01:02","pubTimestamp":1772643739,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘，科伦药业报收于29.22元，下跌1.02%，换手率0.63%，成交量8.28万手，成交额2.43亿元。公司公告汇总2026年度第二期科技创新债券发行结果的公告四川科伦药业股份有限公司2026年度第二期科技创新债券已于2026年3月2日发行，募集资金于3月3日到账。本期债券简称“26科伦 SCP002(科创债)”，代码012680513，期限269日，起息日为2026年3月3日，兑付日为2026年11月27日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500000585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1979443071.USD","BK0060","LU1064131003.USD","LU1934453819.USD","LU2148510915.USD","BK0239","LU1064130708.USD","002422"],"gpt_icon":0},{"id":"2616553293","title":"科伦药业（002422）发布关于首次回购公司股份的公告，3月2日股价下跌1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616553293","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616553293?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:29","pubTimestamp":1772461759,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，科伦药业报收于30.2元，较前一交易日下跌1.11%，最新总市值为482.61亿元。该股当日开盘30.21元，最高30.45元，最低29.51元，成交额达4.56亿元，换手率为1.17%。近日，四川科伦药业股份有限公司发布《关于首次回购公司股份的公告》。本次回购符合相关法律法规及公司已披露的回购方案的规定。公司后续将根据市场情况继续实施回购计划，并按规定履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200039837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","002422","BK0239","LU1064130708.USD","LU1934453819.USD","BK0060","LU1979443071.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2614032360","title":"股市必读：科伦药业（002422）2月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2614032360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614032360?lang=zh_cn&edition=full","pubTime":"2026-02-26 01:04","pubTimestamp":1772039052,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，科伦药业报收于31.02元，上涨0.06%，换手率0.57%，成交量7.51万手，成交额2.33亿元。当日关注点来自交易信息汇总：2月25日主力资金净流入1197.21万元，游资资金同步净流入1242.9万元，显示市场资金积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600000586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU2148510915.USD","LU1064131003.USD","BK0060","LU1979443071.USD","002422","LU1934453819.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2608551877","title":"科伦药业（002422）披露回购公司股份进展公告，2月3日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608551877","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608551877?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:27","pubTimestamp":1770128844,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘，科伦药业报收于30.4元，较前一交易日上涨0.86%，最新总市值为485.81亿元。该股当日开盘30.36元，最高30.48元，最低30.01元，成交额达2.35亿元，换手率为0.6%。近日，科伦药业发布《关于回购公司股份进展的公告》。截至2026年1月31日，公司尚未实施回购。公司将根据市场情况推进回购，并及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300043248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064130708.USD","BK0239","LU1064131003.USD","LU1934453819.USD","002422","BK0060","LU1979443071.USD"],"gpt_icon":0},{"id":"2606975124","title":"科伦药业：公司不涉及该病毒的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2606975124","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606975124?lang=zh_cn&edition=full","pubTime":"2026-01-28 08:12","pubTimestamp":1769559165,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，董秘，请问近期印度爆发尼帕病毒，公司有相关抗病毒药物吗？科伦药业回复：您好，公司不涉及该病毒的药物。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800006984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","002422","BK0239","LU1064130708.USD","LU1934453819.USD","LU1064131003.USD","BK0060","LU1979443071.USD"],"gpt_icon":0},{"id":"2605170537","title":"科伦药业（002422）披露2026年度第一期科技创新债券发行结果，1月21日股价下跌1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605170537","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605170537?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:37","pubTimestamp":1768988220,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，科伦药业报收于32.25元，较前一交易日下跌1.23%，最新总市值为515.37亿元。该股当日开盘32.6元，最高32.66元，最低32.17元，成交额达3.67亿元，换手率为0.87%。近日，科伦药业发布《2026年度第一期科技创新债券发行结果的公告》。公告显示，四川科伦药业股份有限公司2026年度第一期科技创新债券已于2026年1月19日发行，募集资金于1月20日全额到账。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100029324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","LU1064131003.USD","LU1934453819.USD","LU1064130708.USD","002422","LU2148510915.USD","LU1979443071.USD"],"gpt_icon":0},{"id":"2601135664","title":"科伦药业涨6.19%，中国银河二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2601135664","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601135664?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:37","pubTimestamp":1767857866,"startTime":"0","endTime":"0","summary":"今日科伦药业涨6.19%，收盘报33.45元。2025年11月2日，中国银河研究员程培,孙怡发布了对科伦药业的研报《科伦药业2025年三季报业绩点评：业绩短期波动，创新产品持续兑现》，该研报对科伦药业给出“买入”评级。研报中预计公司2025-2027年归母净利润14.83/19.95/23.35亿元，同比增长-50%/35%/17%，当前股价对应2025-2027年PE为37/27/23倍，维持“推荐”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为97.37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601881","002422"],"gpt_icon":0},{"id":"2601525218","title":"科伦药业董事会通过股份回购方案，披露决议前十大股东持股情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2601525218","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601525218?lang=zh_cn&edition=full","pubTime":"2026-01-06 10:16","pubTimestamp":1767665774,"startTime":"0","endTime":"0","summary":"中访网数据 四川科伦药业股份有限公司于2026年1月4日召开第八届董事会第十一次会议，审议通过了《关于回购公司股份方案的议案》。根据相关规定，该议案无需提交股东大会审议。公司于2026年1月6日披露了相关公告。截至该日，公司第一大股东为刘革新，持有379,128,280股，占总股本的23.72%；第二大股东为雅安市国有资产经营有限责任公司，持有96,983,174股，占比6.07%。根据公告，公司将在回购期限内根据市场情况择机实施回购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260106/31918341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1934453819.USD","BK0239","LU1979443071.USD","LU1064130708.USD","BK0060","LU2148510915.USD","LU1064131003.USD","002422"],"gpt_icon":0},{"id":"2601887028","title":"科伦药业(002422.SZ)拟斥5000万元至1亿元实施回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2601887028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601887028?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:43","pubTimestamp":1767624203,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)公告，公司拟使用自有资金以集中竞价交易方式回购公司A股股份。回购资金总额不低于5000万元(含)，且不超过1亿元(含)。回购价格上限35元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1934453819.USD","LU1979443071.USD","BK0239","002422","BK0060","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2590259511","title":"科伦药业（002422）披露控股子公司拟实施2025年股份激励计划，12月11日股价下跌1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590259511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590259511?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:10","pubTimestamp":1765462252,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，科伦药业报收于31.99元，较前一交易日下跌1.6%，最新总市值为511.22亿元。公司近日发布公告称，其控股子公司科伦博泰拟实施2025年股份激励计划，采用受限制股份单位形式，股份来源包括发行新H股、库存股或公开市场购入。该计划最高发行不超过350万股H股，约占总股本的1.5%。本次股份激励计划尚需经科伦博泰股东会批准及联交所批准。公告指出，该计划不会影响科伦药业的合并报表范围，亦不构成重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100041446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","LU2148510915.USD","002422","LU1064131003.USD","LU1934453819.USD","LU1979443071.USD","BK0239","LU1064130708.USD"],"gpt_icon":0},{"id":"2589705339","title":"科伦药业(002422.SZ)：公司5个品种药品纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589705339","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589705339?lang=zh_cn&edition=full","pubTime":"2025-12-08 18:11","pubTimestamp":1765188683,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)公告，据国家医保局、人力资源社会保障部发布《关于印发<国家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药品目录>(2025年)的通知》，公司及其控股子公司共计5个品种纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦药业(002422.SZ)：公司5个品种药品纳入国家医保目录","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1979443071.USD","LU1064131003.USD","LU1064130708.USD","BK0239","002422","LU2148510915.USD","BK0060","LU1934453819.USD"],"gpt_icon":0},{"id":"2588889788","title":"科伦药业最新公告：科伦博泰与CrescentBiopharma建立战略合作伙伴关系涉及科伦博泰的SKB105和Crescent的CR-001两款候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2588889788","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588889788?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:11","pubTimestamp":1764850275,"startTime":"0","endTime":"0","summary":"科伦药业公告称，公司控股子公司科伦博泰与Crescent Biopharma建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段。合作涉及两款候选药物：科伦博泰的SKB105和Crescent的CR-001。科伦博泰授予Crescent在美国、欧洲及大中华地区以外市场开发SKB105的独家权利，而Crescent授予科伦博泰在大中华地区开发CR-001的独家权利。科伦博泰将向Crescent收取8000万美元首付款，并有机会获得高达12.5亿美元的里程碑付款。同时，科伦博泰通过此次合作引入CR-001补充和加强了其差异化的肿瘤研发管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400035319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU2148510915.USD","LU1064131003.USD","BK0060","LU1979443071.USD","002422","LU1934453819.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"1115537632","title":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1115537632","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115537632?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847944,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1064131003.USD","LU1979443071.USD","002422","BK1161","BK0060","LU1934453819.USD","CBIO","LU1064130708.USD","LU0196878994.USD","06990","BK0239","LU2148510915.USD"],"gpt_icon":0},{"id":"1126942018","title":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1126942018","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126942018?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847941,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK1161","BK4139","LU1979443071.USD","BK0239","LU1064131003.USD","LU1934453819.USD","06990","LU2148510915.USD","BK0060","LU0196878994.USD","002422","LU1064130708.USD"],"gpt_icon":0},{"id":"1115079280","title":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1115079280","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115079280?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:30","pubTimestamp":1764847815,"startTime":"0","endTime":"0","summary":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","002422","BK0239","BK1161","BK4139","CBIO","LU0196878994.USD","LU1064130708.USD","LU1934453819.USD","BK0060","LU1979443071.USD","LU2148510915.USD","06990"],"gpt_icon":0},{"id":"2583177683","title":"科伦药业新注册《科伦悦签小程序系统1.0》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2583177683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583177683?lang=zh_cn&edition=full","pubTime":"2025-11-15 00:30","pubTimestamp":1763137838,"startTime":"0","endTime":"0","summary":"证券之星消息，近日科伦药业新注册了2个项目的软件著作权，包括《科伦悦签小程序系统1.0》、《科伦安行通小程序系统1.0》等。今年以来科伦药业新注册软件著作权4个，较去年同期增加了100%。通过天眼查大数据分析，四川科伦药业股份有限公司共对外投资了47家企业，参与招投标项目8624次；财产线索方面有商标信息1138条，专利信息2046条，著作权信息14条；此外企业还拥有行政许可1186个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111500000187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU1934453819.USD","LU1064130708.USD","LU1979443071.USD","BK0239","002422","BK0060","LU2148510915.USD"],"gpt_icon":0},{"id":"2583083415","title":"科伦药业最新公告：棕榈酸帕利哌酮注射液获得药品注册批准为全球首个获批的每月给药一次的长效非典型抗精神病药","url":"https://stock-news.laohu8.com/highlight/detail?id=2583083415","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583083415?lang=zh_cn&edition=full","pubTime":"2025-11-14 19:39","pubTimestamp":1763120381,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告称，公司子公司湖南科伦制药有限公司的化学药品“棕榈酸帕利哌酮注射液”近日获得国家药品监督管理局的药品注册批准。该药品为全球首个获批的每月给药一次的长效非典型抗精神病药，具有提高患者用药依从性、减少疾病复发风险等优势。科伦药业在中枢神经疾病领域已有多个产品获批上市，本次棕榈酸帕利哌酮注射液的获批，将进一步提升公司在中枢神经领域的管线竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400035353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","LU1934453819.USD","BK0239","002422","LU1064131003.USD","LU1064130708.USD","LU1979443071.USD","LU2148510915.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773294078211,"stockEarnings":[{"period":"1week","weight":0.1379},{"period":"1month","weight":0.042},{"period":"3month","weight":0.0394},{"period":"6month","weight":-0.1047},{"period":"1year","weight":0.0438},{"period":"ytd","weight":0.1329}],"compareEarnings":[{"period":"1week","weight":0.0125},{"period":"1month","weight":0.0025},{"period":"3month","weight":0.0672},{"period":"6month","weight":0.0679},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.0415}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37098人(较上一季度增加8.35%)","perCapita":"35200股","listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","registeredCapital":"159805万元","survey":" 四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。","listedPrice":83.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦药业,002422,科伦药业股票,科伦药业股票老虎,科伦药业股票老虎国际,科伦药业行情,科伦药业股票行情,科伦药业股价,科伦药业股市,科伦药业股票价格,科伦药业股票交易,科伦药业股票购买,科伦药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}